{
    "clinical_study": {
        "@rank": "122688", 
        "acronym": "JUPITER", 
        "arm_group": {
            "arm_group_label": "Latanoprostene Bunod", 
            "arm_group_type": "Experimental", 
            "description": "Latanoprostene bunod 0.024% instilled into the eye once daily (QD) over a 1-year treatment period."
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to demonstrate the clinical safety of latanoprostene bunod\n      0.024% once daily (QD) over a 1-year treatment period."
        }, 
        "brief_title": "A Study Evaluating the Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Japanese Subjects With Open-Angle Glaucoma or Ocular Hypertension", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Glaucoma", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must have a diagnosis of open angle glaucoma (OAG) (including normal-tension\n             glaucoma [NTG],pigmentary or pseudoexfoliative glaucoma), or ocular hypertension\n             (OHT) in one or both eyes.\n\n          -  Subjects must meet the following IOP requirements at Visit 3 (Eligibility,\n\n        Day 0[after washout for the subjects already on treatment]):\n\n        mean/median IOP \u2265 15 mmHg and \u2264 36 mmHg at 10 AM in at least 1 eye, and IOP \u2264 36 mmHg in\n        both eyes.\n\n          -  Subjects with a corrected visual acuity (VA) of 0.5 or better in both eyes.\n\n        Exclusion Criteria:\n\n          -  Subjects who are unable to discontinue contact lens use during and for 15 minutes\n             following instillation of study drug and during study visits.\n\n          -  Subjects who are unable to discontinue other eye drop medications such as artificial\n             tears for 15 minutes prior to and 15 minutes after instillation of study drug.\n\n          -  Subjects with a central corneal thickness greater than 600 \u03bcm in either eye.\n\n          -  Subjects with any condition that prevents reliable applanation tonometry in either\n             eye.\n\n          -  Subjects with advanced glaucoma with a mean deviation (MD) < \u221212 dB, a history of\n             split fixation, or a field loss threatening fixation in either eye.\n\n          -  Subjects with any condition that prevents clear visualization of the fundus.\n\n          -  Subjects who are monocular (fellow eye is absent).\n\n          -  Subjects with aphakia in either eye.\n\n          -  Subjects with an active corneal disease in either eye.\n\n          -  Subjects with severe dry eye in either eye.\n\n          -  Subjects with a history/diagnosis of a clinically significant or progressive retinal\n             disease in either eye.\n\n          -  Subjects with very narrow angles and subjects with angle closure congenital, or\n             secondary glaucoma, and subjects with history of angle closure in either eye.\n\n          -  Subjects with any intraocular infection or inflammation within 3 months prior to\n             Visit 1 (Screening).\n\n          -  Subjects with a history of ocular laser surgery within the 3 months (90 days) prior\n             to Visit 1 (Screening).\n\n          -  Subjects with a history of incisional ocular surgery or severe trauma within 3 months\n             prior to Visit 1 (Screening)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01895972", 
            "org_study_id": "811"
        }, 
        "intervention": {
            "arm_group_label": "Latanoprostene Bunod", 
            "intervention_name": "Latanoprostene bunod", 
            "intervention_type": "Drug", 
            "other_name": "BOL-303259-X"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07940"
                }, 
                "name": "Bausch & Lomb Incorporated"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-Arm, Multicenter, Open-Label Study Evaluating the Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Japanese Subjects With Open-Angle Glaucoma or Ocular Hypertension", 
        "overall_contact": {
            "email": "Yosuke.Hagiwara@bausch.com", 
            "last_name": "Yosuke Hagiwara", 
            "phone": "+81-3-5763-3454"
        }, 
        "overall_official": {
            "affiliation": "Bausch & Lomb Incorporated", 
            "last_name": "Quintus Ngumah, OD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Intraocular pressure (IOP) following 1-year of treatment with latanoprostene bunod 0.024% administered once daily to the eye.", 
                "measure": "Intraocular pressure", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Ocular adverse events reported over one year of once daily dosing of latanoprostene bunod 0.024%.", 
                "measure": "Incidence of ocular adverse events (AEs)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Change from baseline in intraocular pressure (IOP) over a 1-year treatment period of latanoprostene bunod 0.024% administered once daily to the eye.", 
                "measure": "IOP (Change from basline)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Systemic adverse events reported over one year of once daily dosing of latanoprostene bunod 0.024%.", 
                "measure": "Systemic AE's", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01895972"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bausch & Lomb Incorporated", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bausch & Lomb Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}